228 related articles for article (PubMed ID: 35499850)
41. Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study.
Nikanorova M; Brandt C; Auvin S; McMurray R
Epilepsy Behav; 2017 Nov; 76():63-70. PubMed ID: 28927712
[TBL] [Abstract][Full Text] [Related]
42. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
[TBL] [Abstract][Full Text] [Related]
43. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.
Sachdeo RC; Glauser TA; Ritter F; Reife R; Lim P; Pledger G
Neurology; 1999 Jun; 52(9):1882-7. PubMed ID: 10371538
[TBL] [Abstract][Full Text] [Related]
44. Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome.
Isojarvi J; Gidal BE; Chung S; Wechsler RT
Epilepsy Behav; 2018 Jan; 78():149-154. PubMed ID: 29202277
[TBL] [Abstract][Full Text] [Related]
45. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.
Motte J; Trevathan E; Arvidsson JF; Barrera MN; Mullens EL; Manasco P
N Engl J Med; 1997 Dec; 337(25):1807-12. PubMed ID: 9400037
[TBL] [Abstract][Full Text] [Related]
46. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
[TBL] [Abstract][Full Text] [Related]
47. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
48. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.
Krauss GL; Klein P; Brandt C; Lee SK; Milanov I; Milovanovic M; Steinhoff BJ; Kamin M
Lancet Neurol; 2020 Jan; 19(1):38-48. PubMed ID: 31734103
[TBL] [Abstract][Full Text] [Related]
49. Clobazam and Aggression-Related Adverse Events in Pediatric Patients With Lennox-Gastaut Syndrome.
Paolicchi JM; Ross G; Lee D; Drummond R; Isojarvi J
Pediatr Neurol; 2015 Oct; 53(4):338-42. PubMed ID: 26245776
[TBL] [Abstract][Full Text] [Related]
50. Fenfluramine HCl (Fintepla
Sullivan J; Scheffer IE; Lagae L; Nabbout R; Pringsheim M; Talwar D; Polster T; Galer B; Lock M; Agarwal A; Gammaitoni A; Morrison G; Farfel G
Epilepsia; 2020 Nov; 61(11):2396-2404. PubMed ID: 33078386
[TBL] [Abstract][Full Text] [Related]
51. [Short-term efficacy and safety of rufinamide for Lennox-Gastaut syndrome].
Takayama R; Fukumura S; Minagawa K; Watanabe T
No To Hattatsu; 2016 Sep; 48(5):322-6. PubMed ID: 30010275
[TBL] [Abstract][Full Text] [Related]
52. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis.
Devi N; Madaan P; Ameen R; Sahu JK; Bansal D
Seizure; 2022 Jul; 99():164-175. PubMed ID: 35487871
[TBL] [Abstract][Full Text] [Related]
53. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
[TBL] [Abstract][Full Text] [Related]
54. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
[TBL] [Abstract][Full Text] [Related]
55. Fenfluramine for the treatment of status epilepticus: use in an adult with Lennox-Gastaut syndrome and literature review.
Strzelczyk A; Becker H; Tako L; Hock S; Hattingen E; Rosenow F; Mann C
Neurol Res Pract; 2024 Feb; 6(1):10. PubMed ID: 38383582
[TBL] [Abstract][Full Text] [Related]
56. Treatment of Adults with Lennox-Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of Rufinamide.
McMurray R; Striano P
Neurol Ther; 2016 Jun; 5(1):35-43. PubMed ID: 26861566
[TBL] [Abstract][Full Text] [Related]
57. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice.
Striano P; McMurray R; Santamarina E; Falip M
Epileptic Disord; 2018 Feb; 20(1):13-29. PubMed ID: 29313492
[TBL] [Abstract][Full Text] [Related]
58. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis.
Tabaee Damavandi P; Fabin N; Giossi R; Matricardi S; Del Giovane C; Striano P; Meletti S; Brigo F; Trinka E; Lattanzi S
Neurol Ther; 2023 Apr; 12(2):669-686. PubMed ID: 36853503
[TBL] [Abstract][Full Text] [Related]
60. Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012.
Isojarvi J; Lee D; Peng G; Sperling MR
Epilepsia; 2016 Jun; 57(6):e113-6. PubMed ID: 27145465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
